What were the design, endpoints, and findings of the OPTIMA trial for early-stage estrogen‑receptor‑positive, HER2‑negative breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

The OPTIMA Trial: A Feasibility Study for Genomic Assay-Guided Chemotherapy Decisions

OPTIMA prelim was a successful UK feasibility study that demonstrated the acceptability and practicality of using multiparameter genomic assays to guide chemotherapy decisions in ER-positive, HER2-negative early breast cancer, paving the way for larger validation trials. 1

Trial Design and Population

OPTIMA prelim (Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study) was designed as a partially blinded randomized controlled trial with adaptive design conducted across 35 UK hospitals between September 2012 and June 2014. 1

Eligible patients included:

  • Women aged ≥40 years
  • Surgically treated ER-positive, HER2-negative primary breast cancer
  • Either 1-9 involved axillary lymph nodes OR node-negative disease with tumor ≥30 mm diameter 1

Study Arms and Intervention

The trial randomized patients between two treatment strategies:

Option 1 (Standard Care): Chemotherapy followed by endocrine therapy

Option 2 (Test-Directed): Oncotype DX testing performed on resected tumor to assign treatment:

  • If Recurrence Score (RS) >25: Standard care (chemotherapy + endocrine therapy)
  • If RS ≤25: Endocrine therapy alone 1

Patients allocated to chemotherapy remained blinded to their randomization assignment, which is a critical design feature to minimize bias. 1

Primary Endpoints and Success Criteria

The trial had pre-specified feasibility endpoints rather than clinical outcomes:

  1. Recruit 300 patients within 2 years
  2. For the final 150 patients specifically:
    • Acceptance rate ≥40%
    • Recruitment completed within 6 months
    • Chemotherapy initiation within 6 weeks of consent in ≥85% of patients 1

Key Findings

The trial successfully met all pre-specified feasibility criteria:

  • 350 patients consented and 313 were randomized (exceeding the 300-patient target)
  • The final 150 patients were recruited in exactly 6 months
  • 92% of patients assigned chemotherapy started treatment within 6 weeks (exceeding the 85% threshold)
  • Acceptance rate was 47% among 750 invited patients (exceeding the 40% target) 1

Important quality control finding: 3.7% (12/325) of patients were deemed ineligible on central review of receptor status, highlighting the importance of centralized pathology review. 1

Multiparameter Assay Comparison

A critical component of OPTIMA prelim was comparing multiple genomic assays on 302 tumor samples to select the optimal test for the main trial. The assays evaluated included:

  • Oncotype DX
  • MammaPrint/BluePrint
  • Prosigna (PAM50)
  • IHC4 and IHC4 AQUA
  • MammaTyper 1

Key observation: While these assays categorized comparable numbers of tumors into low- or high-risk groups, there was only moderate agreement between tests at the individual tumor level (kappa ranges 0.33-0.60 for risk stratification and 0.39-0.55 for molecular subtypes). This finding underscores that different genomic assays are not interchangeable. 1

Economic Analysis

Health economics modeling demonstrated that the value of information to the NHS from further research into multiparameter testing is high, regardless of which test is evaluated. Importantly, Prosigna was identified as the highest priority for further study based on this analysis. 1

Qualitative Research Component

The trial included an integral qualitative recruitment study that provided crucial insights:

  • Interviews with researchers and recordings of patient consultations identified recruitment barriers
  • Three patient focus groups led to modifications in patient information materials
  • These interventions were implemented during the trial to improve recruitment 1

This adaptive approach to addressing recruitment challenges in real-time represents best practice in trial design.

Clinical Implications and Future Directions

OPTIMA prelim achieved its primary aim: demonstrating that a large UK clinical trial of multiparameter assay-based chemotherapy selection in hormone-sensitive early breast cancer is feasible and would be economically worthwhile for the NHS. 1

The success of this feasibility study directly informed the development of OPTIMA-YOUNG, an EU-funded international trial investigating genomic assay-guided chemotherapy de-escalation specifically in premenopausal patients with early-stage HR-positive breast cancer. 2 This extension addresses a critical knowledge gap, as premenopausal women often experience greater treatment burden affecting their physical and psychosocial well-being. 2

Important Caveats

OPTIMA prelim was a feasibility study, not a clinical efficacy trial. It did not provide evidence about whether genomic assay-guided treatment decisions improve patient outcomes compared to standard clinical decision-making. The trial's success means that such evidence can now be generated through appropriately powered randomized controlled trials.

The moderate agreement between different genomic assays highlights that test selection matters—clinicians cannot assume different assays will provide equivalent guidance for individual patients, even if they classify similar proportions of the overall population into risk categories. 1

Related Questions

Could long-term testosterone therapy have caused breast cancer in a 34-year-old transgender man with hormone-receptor-positive, HER2-negative, stage IIB invasive ductal carcinoma, considering his family history of colon cancer and leukemia?
For a 45-year-old premenopausal woman with a 1.8 cm grade 1 hormone‑receptor‑positive, HER2‑negative, node‑negative invasive ductal carcinoma and a Recurrence Score of 18, is four cycles of adjuvant docetaxel‑cyclophosphamide (TC) the appropriate chemotherapy regimen?
What adjuvant therapy is recommended for a 45-year-old premenopausal woman with an 18 mm grade 1 hormone‑receptor‑positive HER2‑negative invasive ductal carcinoma and negative sentinel nodes after lumpectomy?
In a 56-year-old postmenopausal woman with invasive ductal carcinoma that is estrogen receptor (ER) and progesterone receptor (PR) positive, HER2 negative, who has completed adjuvant chemotherapy and mastectomy, what is the next recommended treatment?
What is the best treatment option for a 33‑year‑old G3P2 woman with stage III invasive breast cancer that is HER2‑positive and estrogen‑ and progesterone‑receptor negative, who is 13 weeks pregnant (first trimester) and not in labor?
In a patient with atrial fibrillation with rapid ventricular response and a QRS duration of 126 ms, what is the clinical significance and recommended management?
In a hypertensive patient with bilateral renal artery stenosis who is currently on amlodipine and an ACE inhibitor or ARB, how should the antihypertensive regimen be adjusted?
What are the guidelines for excising a primary cutaneous melanoma?
What is the recommended amoxicillin dose for dental prophylaxis in adults and children, and what alternative regimens are used for penicillin‑allergic patients?
Is it advisable to initiate sertraline at a half tablet (~12.5 mg) instead of the standard 25 mg daily dose?
How should an optimal clinical trial be designed for an adult (18‑65) patient with moderate‑to‑severe opioid use disorder receiving buprenorphine/naloxone, including induction dosing, randomization arms, inclusion criteria, and primary and secondary outcomes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.